


PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg
C r tificat



Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande AbSorber AB, Huddinge SE
Applicant (s)

(21) Patentansökningsnummer 9903021-5
~~Patent application number~~

(86) Ingivningsdatum 1999-08-26
Date of filing

Stockholm, 2000-10-31

För Patent- och registreringsverket
For the Patent- and Registration Office

A. Södervall
Anita Södervall

Avgift
Fee

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

Reduction of the immunogenicity of non-human grafts

The present invention relates to the use of molecules that bind to macrophages and/or microglial cells in order to mask and/or remove macrophages and/or microglial cells in order to treat a non-human graft to diminish the immunogenicity and/or rejection of the graft. The molecule could bind to the Gal α 1-3Gal epitope and could e.g. be an antibody. The graft could e.g. be a porcine neural graft. The invention also relates to a process for removal of cells, such as macrophages and/or microglial cells. The invention also relates to a process for preparation of an antibody as mentioned above. Furthermore, the invention relates to an antibody that binds to macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope, as well as a composition comprising such an antibody and a complement reagent. Finally, the invention relates to a process for treatment of neurological disorders with such pretreated porcine neural grafts.

15

Background of the invention

Neural transplantation is a potential therapy for Parkinson's and Huntington's diseases (Peschanski et al., 1995; Olanow et al., 1997; Borlongan et al., 1999; Dunnett and Björklund, 1999). Due to the short supply of human donor material (Dunnett and Björklund, 1999), tissue derived from an animal source is considered an appropriate alternative (Isacson and Breakefield, 1997; Edge et al., 1998), and has the advantage of being genetically modifiable (Cozzi and White, 1995; Zawada et al., 1998). When implanted into the striatum of immunosuppressed rats, ventral mesencephalic tissue from pig embryos can grow anatomically correct connections (Isacson et al., 1995) and restore induced behavioural deficits (Huffaker et al., 1989; Galpern et al., 1996). So far, porcine neural tissue has been grafted to 12 Parkinson and 12 Huntington patients in small-scale safety trials (Edge et al., 1998).

Porcine neural grafts are, however, prone to immune-related rejection in the human brain (Deacon et al., 1997). Rejection of murine neural grafts can be prevented by

treatment of rat hosts with antibodies against T lymphocytes of the immune system (Okura et al., 1997). The human T-cell repertoire includes cells that are activated by porcine major histocompatibility complex (MHC) antigens on porcine cells (direct recognition), and cells that are activated by peptides derived from porcine proteins after processing and presentation by human antigen presenting cells (indirect recognition) (Satake et al., 1994; Dorling et al., 1996). For direct recognition to occur, the porcine donor cells must express class I and/or class II MHC antigens, which are recognised by CD8 and CD4 T lymphocyte cells, respectively. Survival of human neural tissue in mouse brain can be prolonged by depletion of host CD4, but not CD8 T cells (Wood et al., 1996), proving that CD4 T cells are essential for neural xenograft rejection, which is also the case for rejection of non-neural xenografts (Pierson et al., 1989; Kaufman et al., 1995; Korsgren, 1997). In vitro, pig MHC class II antigens elicit a much stronger proliferative response in human T cells than pig MHC class I antigens (Kirk et al., 1993; Kumagai-Braesch et al., 1993; Yamada et al., 1995; Dorling et al., 1996), suggesting that cells which express MHC class II antigens, or have the potential to express these molecules once implanted, contributes heavily to the immunogenicity of the donor tissue. MHC class II antigens have not been reported in neurons (Lampson, 1995).

Cyclosporin, an immunosuppressant that inhibits alloreactivity, is inadequate at protecting porcine xenografts from immune attack in rats (Wennberg et al., 1995). Continuous cyclosporin treatment of rats hosting porcine neural grafts resulted in some degree of graft survival in 74% of the animals 3-4 months after transplantation (Pakzaban et al., 1995). A Parkinson patient that received porcine neural grafts and continuous cyclosporin treatment had poorly surviving grafts 7.5 months after transplantation, considering that 1.2×10^7 cells were implanted and only 638 dopaminergic cells were present at post-mortem histology (Deacon et al., 1997). In the clinical setting, the immunosuppression must therefore be more aggressive, which may have serious consequences in terms of side effects (Borlongan et al., 1996), or supplemented by reduction of donor tissue immunogenicity prior to transplantation.

Summary of the invention

It has now been shown that when dissociated brain tissue from pig embryos is grown in primary culture, its macrophages and/or microglial cells become autofluorescent, express both classes of MHC antigens and induce proliferation of T lymphocytes, while its astrocytes remain non-autofluorescent, only express MHC class I antigens, and only generate a weak proliferative response in human T cells (Brevig et al., 1999, in press). In attempts to remove macrophages and/or microglial cells from porcine brain tissue, a potential target according to the invention is the carbohydrate epitope Gal α 1-3Gal β 1-R (α -galactosyl epitope), which the inventors have now demonstrated on macrophages and/or microglial cells and endothelial cells, but not on neurons and astrocytes, in embryonic pig brain (Sumitran et al., 1999, in press). Human serum

contains a high titer of naturally occurring, complement-activating IgG and IgM antibodies against the α -galactosyl epitope (anti-Gal) (Galili, 1993; Rother and Squinto, 1996), but also antibodies against other epitopes expressed in ventral mesencephalon of pig embryos (Sumitran et al., 1999, in press). Purified anti-Gal and complement may thus have the ability to selectively lyse macrophages and/or microglial cells and endothelial cells thus removing them from porcine neural suspension grafts prior to transplantation.

As described above, neural xenograft survival is compromised by host CD4 T lymphocytes. In order to reduce the immunogenicity of porcine embryonic brain tissue, which is of interest as donor material in therapeutic xenografting for e.g. Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy and spinal cord injuries, the possibility of using the Gal α 1-3Gal β 1-R epitope (α -galactosyl epitope) as target for antibody- and complement-mediated removal of macrophages and/or microglial cells has been studied in vitro by the inventors. After exposing brain cells isolated from 27-day-old pig embryos to antibodies against the α -galactosyl epitope (anti-Gal) and complement, the remaining cells were (i) analysed by flow cytometry to determine the content of macrophages and/or microglial cells, and (ii) co-cultured with human peripheral blood CD4 T lymphocytes to determine their ability to elicit a

proliferative T-cell response, which was assessed by measuring incorporation of tritiated thymidine. Incubation of porcine embryonic brain cells with normal human serum, which contains a high anti-Gal titer, followed by rabbit complement reduced the number of macrophages and/or microglial cells, both when applied to freshly isolated cells and to cells grown in short-term primary culture. Cultured porcine embryonic brain cells treated with purified human anti-Gal and rabbit complement contained 0.8% macrophages and/or microglial cells and did not induce proliferation of human CD4 T cells, while brain cells given a control treatment with medium and rabbit complement contained 3.4% macrophages and/or microglial cells and induced a significant proliferative response in human CD4⁺ T lymphocytes.

Detailed description of the invention

One object according to the invention is the use of molecules that bind to macrophages and/or microglial cells in order to mask and/or remove macrophages and/or microglial cells in order to treat a non-human graft to diminish graft immunogenicity and/or rejection in the human body. By the term molecule is meant any molecule that could bind to and mediate the separation of macrophages and/or microglial cells from astrocytes and/or neurons in a non-human graft and prevent the proliferation of lymphocytes in the grafted host.

The molecule is preferably a molecule that binds to an epitope containing the Gal α 1- and 3Gal β 1-sugar residues, preferably Gal α 1-3Gal β 1-R terminated epitopes. An example of such an epitope is the Gal α 1-3Gal β 1-4GlcNAc-R epitope.

The Gal α 1-3Gal β 1-R antigen and the isolation thereof is described in Subcellular Biochemistry, Vol. 32: alpha-Gal and Anti-Gal, edited by Galili and Avila. Kluwer Academic/Plenum Publishers, New York, 1999; Liu et al. (1997); and Hallberg et al. (1998).

The molecule could be any substance, but is preferably an antibody. Examples of such an antibody is a monoclonal or polyclonal antibody. The antibodies may derive from any species, but are preferably human. The term monoclonal antibody is art-recognised terminology. Monoclonal antibodies of the present invention can be prepared according to general methods as described in Kohler et al., 1975. A polyclonal antibody is an antibody that could be purified from serum. There is also a possibility to create new molecules that binds to the epitope by means of computer simulation. Methods for computer simulation are known by a person skilled in the art, e.g. as described in EP 0660 210 A2.

10

The non-human graft is preferably a porcine graft, e.g. a porcine neural graft, in particular a graft derived from porcine embryonic and/or fetal neural tissue.

- Another object of the invention is a process for removal of macrophages and/or microglial cells from non-human grafts, characterised in that
- (a) the graft, preferably an embryonic and/or fetal neural tissue, is dissociated, possibly also converted to a single-cell suspension,
 - (b) the dissociated tissue is treated with a molecule that binds to macrophages and/or microglial cells, preferably an antibody, especially an antibody against the Gal α 1-3Gal β 1-R epitope, and possibly also a complement reagent,
 - (c) the macrophages and/or microglial cells are deleted from the graft by coupling of the binding molecule to a carrier or by flow sorting, or
 - (d) the macrophages and/or microglial cells are lysed with the antibody and the complement reagent.

25

In the process above it is preferred that

- (a) porcine embryonic and/or fetal neural tissue is dissociated,
- (b) the dissociated tissue is treated with antibodies, preferably human antibodies, against the Gal α 1-3Gal β 1-R epitope and complement reagent in order to remove and/or mask macrophages and/or microglial cells.

30

Preferably, the disorders are selected from the group consisting of Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy and spinal cord injuries.

- 5 It is preferred to dissociate the graft tissue and use antibody- and complement-mediated lysis, since even macrophages and/or microglial cells within small cell clusters can be removed by this mechanism.

- 10 It is also possible to convert the graft tissue to a single-cell suspension and physically remove macrophages and or microglial cells e.g. by panning, paramagnetic beads, or flow sorting although this may lower the amount of usable nerve cells. See Current Protocols in Immunology, edited by Coligan, J.E. et al. 1993, vol. 1-3, John Wiley & Sons, Inc.

- 15 Another object of the invention is a process for preparation of an antibody that binds to macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope, characterised in that the antibody is purified from human serum from blood type AB donors by affinity chromatography with, for example, porcine thyroglobulin as a source of the epitope.

- 20 Another object of the invention is an antibody against macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope. The antibody could be obtained by the process described above for preparation of said antibody.

- 25 Another object of the invention is a composition, comprising said antibody, together with a complement reagent. Preferably, the complement reagent is Low-Tox-M complement.

- 30 Another object of the invention is a process for treatment of neurological disorders, characterised in that
(a) porcine embryonic and/or fetal neural tissue is dissociated,

- (b) the dissociated tissue is treated with antibodies, preferably human antibodies, against the Gal α 1-3Gal β 1-R epitope and complement in order to remove and/or mask macrophages and/or microglial cells,
- (c) the dissociated and antibody- and complement-treated tissue is transplanted into the human body.

Preferably, the disorders are selected from the group consisting of Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy and spinal cord injuries.

- 10 Instead of transplanting whole suspensions prepared from porcine brain tissue, the inventors propose that the dissociated tissue should be pretreated with anti-Gal and complement, the effect of which is shown in Figure 13. If the pretreatment with anti-Gal and complement can enhance survival of porcine neural grafts in humans, it may serve as a simple and inexpensive way of reducing donor tissue immunogenicity prior to clinical neural xenotransplantation.

- After neural xenotransplantation, both direct and indirect recognition of the graft may occur, but the relative strength of these two mechanisms is not known in the pig-to-man xenograft situation (Gill and Wolf, 1995; Auchincloss and Sachs, 1998). The inventors have focused on direct recognition, but the pretreatment with anti-Gal and complement might also reduce indirect recognition, due to the removal of cells and thus proteins carrying the α -galactosyl epitope, which can be opsonized by host anti-Gal for endocytosis, processing, and presentation by host antigen presenting cells. Since proteins against which there are no preformed antibodies in the host also can be recognised indirectly by host T cells, even neurons may be immunogenic. As a consequence, porcine neural xenografts cannot be made completely non-immunogenic.

Short description of the figures

- 30 Figure 1. Flow cytometric analysis of unstained brain cells from 28-day-old pig fetuses.

Figure 2. Expression of CD18, CD56, CD44, CD4, and GFAP by cells isolated from 28-day-old fetal pig brains and grown for 14 days in primary culture.

5 Figure 3. Phagocytosis of *Escherichia coli* by cultured cells from 28-day-old fetal pig brains.

Figure 4. Flow sorted astrocyte and macrophage populations, separated on the basis of cell granularity and autofluorescence.

10 Figure 5. Flow sorted astrocyte and macrophage populations, separated on the basis of CD56 expression.

Figure 6. Expression of α -galactosyl epitopes on suspended VM cells and PLMECs.

15 Figure 7. Western blot analysis of BS-IB4 reactive, solubilized glycoprotein isolated from cell membranes.

20 Figure 8. Saggital section of the VM of a 27 day-old pig embryo stained immunohistochemically for tyrosine hydroxylase.

Figure 9. Expression of the α -galactosyl epitope on cultured porcine embryonic brain cells.

25 Figure 10. Effect of human serum and rabbit complement on cultured and freshly isolated porcine embryonic brain cells.

30 Figure 11. Reactivity towards the α -galactosyl epitope of the antibodies purified from normal human serum using porcine thyroglobulin.

Figure 12. Proliferative response of CD4 T lymphocytes from two human individuals when co-cultured with pretreated porcine embryonic brain cells.

Figure 13. Summary of the effect of anti-Gal and complement on dissociated porcine brain tissue in the clinical situation and in an in-vitro model.

The invention will now be described by reference to some non-limiting examples

As used herein, the following terms have the following meanings:

10

BSA means bovine serum albumin,

DMEM means Dulbecco's modified Eagle's medium,

~~EDTA means ethylenediaminetetraacetic acid.~~

FCS means fetal calf serum,

15 FITC means fluorescein isothiocyanate,

FBS means fetal bovine serum,

Gal means D-galactose,

GlcNAc means D-N-acetylglucosamine,

Ig means immunoglobulin,

20 mAb means monoclonal antibody,

PBS means phosphate buffered saline,

PMSF means phenylmethane sulfonyl fluoride,

PLMEC means porcine liver microvascular endothelial cell,

RPE means R-phycoerythrin,

25 TH means tyrosine hydroxylase,

TNF means tumour necrosis factor,

VCAM means vascular cell adhesion molecule, and

VM means ventral mesencephalon.

30

All technical and scientific terms used herein are, unless otherwise defined, intended to have the same meaning as commonly understood by one of ordinary skill in the art. By

the expression "comprising" we understand including but not limited to. Techniques employed herein are those that are known to one of ordinary skill in the art unless stated otherwise. Publications mentioned herein are incorporated by reference.

5 Examples

Materials and methods

For Example 1 and 2 (See also for Example 4-7)

10

Porcine fetal brain cells. Brain cells were isolated from whole brain or ventral mesencephalon of 28, 35, 42, and 56 days old pig fetuses (Table 1). Brains isolated from each of the 12 litters of 6-15 fetuses were pooled in Gey's Balanced Salt Solution (Life Technologies, Scotland) and meninges were carefully removed. The brains were
15 cut into small pieces, transferred to brain-cell medium (Eagle's Minimum Essential Medium with Earle's Salts supplemented with L-glutamine, amino acids, vitamins (all Life Technologies), penicillin, hexamycin, and sodium bicarbonate) with 20% heat-inactivated (56°C, 30 min) horse serum (Life Technologies), triturated with a flame-polished pipette, and finally filtered through a Nitex filter with 80-µm pores. The
20 filtrates were diluted in brain-cell medium with 20% horse serum to give total volumes of 10, 20, 30, or 50 ml per 28, 35, 42, or 56 days old brain, respectively.

The brain cells were analysed directly after isolation or after 12-14 days in primary culture. Cultures were prepared by adding 5.0 ml cell suspension, prepared as
25 described above, to poly-D-lysine (Sigma, USA) coated culture flasks (50-ml flasks; Nunc, Denmark), followed by incubation at 37°C in a humidified atmosphere of 5% CO₂ in air. After 2 days, when the cells had attached, the medium was changed to brain-cell medium with 20% horse serum, and subsequently twice a week to brain-cell medium with 10% horse serum.

25

30

The cultured brain cells were detached by gently sweeping the bottoms of the culture flasks with a plastic pipette (culture flasks were checked by microscopy to ensure that all cells had detached), transferred to V-bottomed tubes (content of one flask to one tube), and centrifuged (100 g, 10 min). The supernatants were discarded, each tube was given either 500 µl CellWash (for flow cytometry and flow sorting; Becton Dickinson (BD), USA) or 500 µl lymphocyte medium (for co-culture with human lymphocytes; see below), and the cells were resuspended using a syringe with a needle of 0.5 mm internal diameter. The tubes were left for 15 min at room temperature to sediment cell clusters, and the supernatants with single cells in suspension were harvested and used for subsequent analyses.

Staining reagents. For immunofluorescence staining of the brain cells, the following primary antibodies and antibody-fluoreochrome conjugates were used: mouse anti-MHC I IgG_{2a} (immunogen: pig thymus; 1:10; clone PT85A; Veterinary Medical Research and Development (VMRD), USA), mouse anti-MHC II IgG_{2a} (immunogen: thymus from pig and other species; 1:10; clone TH16B; VMRD), mouse anti-pig CD4 IgG_{2a} (1:1; clone PT90A; VMRD), mouse anti-pig CD44 IgG_{2a} (1:1; clone PORC24A; VMRD), mouse anti-human CD18 IgG₁ FITC (1:1; clone MHM23; DAKO, Denmark), mouse anti-human CD56 IgG₁ RPE (1:1; clone MY31; BD), or polyclonal rabbit anti-cow GFAP (1:10; DAKO). Goat anti-mouse immunoglobulins F(ab')₂ RPE (1:10; DAKO) was used as secondary reagent for the MHC antibodies and the antibodies against CD4 and CD44. Swine anti-rabbit immunoglobulins FITC (1:10; DAKO) was used as secondary antibody for the GFAP antibody. Samples exposed to species- and isotype-matched irrelevant antibody (mouse IgG_{2a} negative control (1:1; DAKO) or mouse IgG₁ negative control FITC/RPE/Cy5 (1:1; DAKO)) or secondary antibody only were used as negative controls. According to the manufacturers, primary antibodies against antigens from other species than pig cross-reacted strongly with the corresponding pig antigens. Higher concentrations of antibodies than indicated did not give stronger staining. Staining reagents for demonstration of phagocytosis are given below.

Staining procedures. Brain cells from cultures derived from the same brains were pooled prior to staining to eliminate possible variability between cultures. Volumes of 100 μ l cell suspension containing 1.0×10^6 freshly isolated or cultured brain cells were transferred to Falcon tubes (BD) and given 10 μ l antibody. After 30 min in the dark at room temperature, the cells were washed twice in CellWash (250 g, 5 min) and resuspended in 100 μ l CellWash for indirect immunostaining or 500 μ l CellWash for direct immunostaining. Samples for indirect immunostaining were given 10 μ l secondary antibody, incubated and washed as described above, and resuspended in 500 μ l CellWash. Prior to staining for GFAP, the cells were fixed and permeabilized in the Falcon tubes by incubating them for 10 min in 2.0 ml FACS Lysing Solution (BD), and subsequently for 10 min in 0.5 ml FACS Permeabilizing Solution (BD).

For demonstration of phagocytosis, 0.5 mg fluorescein-labelled *Escherichia coli* BioParticles (Molecular Probes, USA) was added to the medium of brain-cell cultures. After 30 min of incubation at 37°C, the cells were washed twice in CellWash, detached, dissociated, and analysed by flow cytometry, fluorescence microscopy, or confocal laser microscopy. Prior to receiving the *E. coli* BioParticles, cultures to be analysed by confocal laser microscopy were given 20 μ l 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes) stock solution (1.0 mg DiI per ml 99% ethanol), incubated for 2 h at 37°C, and washed twice in brain-cell medium with 10% horse serum.

Flow cytometry. Brain cells were stained as described above, and 1.0×10^4 ungated events were acquired from each sample on a FACScan flow cytometer (BD). A forward-scatter threshold was set to exclude subcellular debris. The instrument settings were identical for all acquisitions, except for the fixed cells, where the forward-scatter threshold was reduced.

Confocal laser scanning microscopy. Drops of suspended brain cells were placed on microscopy slides and covered by coverslips for ordinary fluorescence microscopy.

Suitable parts of the samples were then scanned by a Leica TCS 4D DM R confocal laser scanning microscope (Leica, Germany) in dual-channel mode using excitation wavelengths of 488 and 568 nm, detectors with fluorescein and rhodamine optical filter sets, and linear AD converting.

5

Flow sorting. In order to separate astrocytes and macrophages, single-cell suspensions of cultured brain cells, prepared as described above, were sorted at a rate of $2-3 \times 10^3$ cells/s on a FACSVantage cell sorter (BD) equipped with a Helium-Neon laser (488 nm), an FL1/FL2 beam splitter (560 nm), and FL1 (530 ± 15 nm) and FL2 (575 ± 13 nm) filters. In the first protocol, unstained brain cells were sorted by setting rectangular gates in a forward-scatter/side-scatter plot and in a green-fluorescence/orange-fluorescence plot to sort cells with high side scatter and high autofluorescence (macrophages) into one tube, and cells with low side scatter and low autofluorescence (astrocytes) into another. In the second protocol, 6.0×10^7 brain cells, in 5.0 ml CellWash with 2% FCS, were given 200 μ l mouse anti-CD56 IgG₁ RPE, incubated for 30 min at 4°C, washed twice in CellWash with 2% FCS (250 g, 5 min), and sorted by setting rectangular gates in a green-fluorescence/orange-fluorescence plot to sort CD56-positive cells (astrocytes) into one tube, and autofluorescent, CD56-negative cells (macrophages) into another. The sample fluid was CellWash in the first protocol, and CellWash with 2% FCS in the second protocol. In both protocols, FACSType (BD) was used as sheath fluid. A forward-scatter threshold was set to exclude subcellular debris in both protocols.

To determine the purity of the cell populations sorted by the first protocol, volumes of 300 μ l cell suspension containing 1×10^5 brain cells were transferred to Falcon tubes and given 30 μ l mouse anti-CD56 IgG₁ RPE. After 30 min in the dark at room temperature, the cells were washed twice in CellWash (250 g, 5 min), resuspended in 300 μ l CellWash, and analysed on a FACScan flow cytometer (as described above). To determine the viability of the cell populations sorted by the first protocol, volumes of 300 μ l cell suspension containing 1×10^5 brain cells were transferred to Falcon tubes

and given 5 μ l propidium iodide (Sigma) solution (100 μ g propidium iodide per ml PBS). After 10 min in the dark at room temperature, the samples were analysed by flow cytometry.

- 5 The purity of the cell populations sorted by the second protocol was determined by flow cytometry without further staining of the cells. The viability of the macrophages sorted by the second protocol was determined by flow cytometry after staining with propidium iodide (as described above). The viability of the astrocytes sorted by the second protocol was determined by counting the blue cells and the total number of cells, 10 min after mixing aliquots of 0.4% trypan blue solution (Sigma) and cell suspension.

Mixed lymphocyte-brain cell culture. Mononuclear blood cells (lymphocytes and

- 15 monocytes) from 3 healthy blood donors (H-3970, H-3977, and H-8053) were isolated from buffy coats by flotation and cryopreserved as earlier described (Brevig et al., 1997). Prior to use, the cells were thawed in a water bath (37°C), washed (500 g, 10 min) 3 times in RPMI (Life Technologies), and left for 24 h in *lymphocyte medium* (90% RPMI 1640 with HEPES, 10% heat-inactivated FCS, 100 IU/ml penicillin, 100 μ g/ml streptomycin, and 2.0 mM L-glutamine; all Life Technologies) at 37°C in a humidified atmosphere of 5% CO₂ in air. Volumes of 100 μ l lymphocyte medium containing 2.0×10^5 human mononuclear blood cells (responders) were dispensed in wells of U-bottomed microtiter plates (Nunc). Unseparated brain cells, sorted brain cells, and allogeneic mononuclear blood cells (stimulators) were γ -irradiated (50 Gy), and 2.0×10^4 cells in 100 μ l lymphocyte medium were added to wells with responders (3 or 5 wells per combination). Wells receiving responders and lymphocyte medium but no stimulators were used as negative controls (5 or 12 wells per combination). Each well was given 1.0 μ Ci [³H]-thymidine (Amersham, UK) 24 h prior to cell harvest. After 4 days of incubation at 37°C in a humidified atmosphere of 5% CO₂ in air, cells were harvested with a cell collection system (Skatron, Norway) and counted in a β -counter (2000CA Tri-Carb; Packard, USA).
- 25
30

Statistical analysis. The proliferation data were analysed by one-way analyses of variance (ANOVAs) and one-sided, unpaired *t* tests.

5 For Example 3 (See also for Example 4-7)

Cell culture. The immortalised human umbilical vein endothelial cell line, ECV304 (ATCC; CRL-1998) was cultured in DMEM/FBS. Porcine liver microvascular endothelial cells (PLMECs) were isolated from fresh pig livers obtained from the local slaughter house. The specimens were chopped to pieces in medium containing 0.05% (w/v) collagenase (cat. no. 1 088 793; Boehringer Mannheim; Mannheim, Germany) and 0.002% (w/v) DNase I type II from bovine pancreas (cat. no. D-4527 ; Sigma), followed by digestion at 37°C for 30-45 min. The cell suspension was filtered to remove undissociated tissue, washed three times with PBS, and cultured for 1 week in 0.2% gelatin-coated 25 cm² flasks (Falcon) using the medium indicated below. Expanded cells were activated for 18 hours with 100 U/ml human recombinant TNF- α (Genzyme, Cambridge, USA), incubated on a rock n' roller for 1 hour at room temperature with 50 μ g (1 mg/ml) of anti-pig VCAM antibodies (clone 5D11; Alexion Pharmaceuticals, New Haven, CT), washed once with PBS, and incubated with 100 μ l of paramagnetic goat anti-mouse DYNA beads (DYNAL, Norway) at 4 °C for 45 minutes followed by immunomagnetic selection on a magnet. Positively selected cells were washed three times with PBS and cultured in gelatin-coated six well tissue culture plates (Falcon plastics) in DMEM medium containing 10% fetal bovine serum (Gibco), penicillin (100 IU/ml; Sigma) and streptomycin (100 μ g/ml; Sigma), and 1 ml/100 ml medium of endothelial cell growth factor (cat. no. E-9640; Sigma). On the second day of culturing, the beads were washed away using PBS. The cells were allowed to grow to confluence before subculturing. Endothelial cells were characterised by morphology, and by flow cytometric phenotyping using anti-E-selectin (clone BBIG-E4; cat. no. BBA 16; R&D systems, Oxford, U.K.) and anti-porcine VCAM antibodies. More than 95 % were ECs.

- Isolation of pig embryonic ventral mesencephalic cells.* Ventral mesencephalic (VM) regions were obtained from E26-27 pig embryos of the Pigham strain (derived from a cross between Swedish Landrace x Yorkshire sows and Hampshire boars; Nyholms Breeding farm, Sweden). Pigs were bred and euthanized according to local and national animal ethics regulations. The VM cells contained approximately 10-15% dopaminergic cells, the rest being other neurons, glia, microglial cells and endothelium. The tissue was dissected in Hank's balanced salt solution with 0.3 μ M lazaroïd U-83836E (Upjohn Inc.) (Nakao et al., 1994). A VM tissue specimen, about 2 x 2 x 1 mm was cut into 4-6 smaller pieces and these were transferred to cold storage medium (Grasbon-Frodl et al., 1996) and shipped to Huddinge Hospital for analysis the same or the following day. The tissue was then triturated into a cell suspension by several passages through a pipette. Prior to shipping and *in vitro* analysis, the viability was checked using ethidium bromide.
-
- 15 *Flow cytometric assays.* Five times 10^5 VM cells in 50 μ l PBS, were incubated with 50 μ l human AB serum, anti-Gal antibody-depleted AB serum or RPMI 1640 medium for 1 hr at 22°C. The cells were washed three times with PBS containing 0.1% sodium azide. Ten μ l of 1:4 diluted FITC-conjugated F(ab)'₂ fragments of goat anti-human IgG or IgM antibodies (109-096-098 and 109-096-129, respectively; Jackson
- 20 ImmunoResearch Labs) were added and incubated on ice in the dark for 25 min. The cells were washed and then analysed by flow cytometry. α -galactosyl epitope expression was estimated by incubating VM cells or PLMECs with biotinylated *Bandeiraea simplicifolia* isolectin B4 (4 μ g/ml; cat.no. L-2140; Sigma) followed by detection with FITC-conjugated avidin (cat.no. 55880; Organon Teknika, Durham,
- 25 NC) diluted 1:2000 in 1 % BSA/PBS. Alternatively, 200 μ l of rabbit serum (Cat. no. 439665, Biotest AG, Dreieich, Germany) was added to tubes containing 5 x 10^5 VM cells in 50 μ l PBS and 50 μ l human AB serum, anti-Gal antibody-depleted AB serum or RPMI 1640 medium and incubated further for 1 hour. Dead cells were detected by adding 5 μ l propidium iodide (PI; 3.2 mM in PBS) immediately prior to analysing the
- 30 samples on the flow cytometer (FACScan; Becton Dickinson, Mountain View, California) equipped with an argon laser exciting at 488 nm (Jacobs et al., 1983). Data

was collected with logarithmic amplification and fluorescence intensity was displayed as arbitrary linear units. Fluorescence signals from 10,000 cells were acquired.

Staining of porcine embryonic VM tissue with anti-tyrosine hydroxylase, anti-monocyte/macrophage antibodies or the isolectin Bandeiraea simplicifolia IB4. Whole heads from E26/E27 embryos were cut, immersion fixed in cold 0.1 M phosphate buffered 4% paraformaldehyde (pH 7.4) over night, followed by an incubation in a 20% sucrose-PBS solution for at least 24 hours. The specimens were frozen, and four serial, 40 µm coronal sections were cut on a sliding microtome. Free-floating sections were stained.

For tyrosine hydroxylase and microglial cell immunostaining, standard immunohistochemical methods were used (Duan et al., 1995). Endogenous peroxidase activity was removed with a 3% H₂O₂/10% methanol solution, followed by a 1 hour incubation in 5% swine serum. Sections were incubated over night in rabbit anti-TH (1:500; Pel-Freez, Rogers, Ark., USA) or in mouse anti-human monocyte/macrophage (1:500; clone MAC387; IgG₁; Serotec, Oxford, England) mAbs diluted in PBS (pH=7.2-7.4) with 0.3% Triton X-100 (PBS-X) at room temperature. The latter antibody binds microglial cells and cross-reacts with swine (Serotec, Oxford, England). The following day, sections were rinsed three times in PBS-X and incubated for 1 hour with biotinylated swine anti-rabbit antibody (1:200; Dakopatts, Copenhagen, Denmark) or with a polyclonal biotinylated horse anti-mouse IgG antibody (1:200; clone BA-2001; Vector Labs, Burlingame, CA, USA), respectively. After rinsing in PBS-X, the Vectastain™ standard peroxidase ABC kit was used (Vector Labs, Burlingame, CA, USA). After 1 hour, the sections were washed three times in PBS-X and visualised using a DAB (3,3'-diaminobenzidine) kit, (Vector Labs). Sections were mounted on gelatin slides, dehydrated by standard alcohol/xylene dehydration, and covered with DePeX slips (BDH Labs, Poole, UK).

For isolectin staining with BS-IB4, sections were treated with a 3% H₂O₂/10% methanol solution to block endogenous peroxide activity followed by a 1 hour

incubation in 1% BSA blocking solution. Sections were incubated overnight (4°C) in a 4 µg/ml solution of biotinylated BS-IB4 (Sigma, L-2140) diluted in PBS (pH=6.8) containing 0.2 mM CaCl₂ (PBS-Ca). On the following day, sections were washed in PBS-Ca three times and then incubated at room temperature with the AB solution contained in the Vectastain™ standard peroxidase ABC kit (Vector Labs.). After rinsing in PBS-Ca the sections were reacted with a DAB solution prepared using the Vector™ Dab kit (Vector Labs). Sections were mounted on gelatin slides, dehydrated by standard alcohol/xylene dehydration, and covered with DePeX (BDH Labs) glass slides.

10

Isolation of endothelial and VM cell membranes. Cells were washed once with PBS containing 1 mM PMSF and kept frozen at -70 °C until use. Following six cycles of freeze thawing, cells were homogenised on ice in PBS/1 mM PMSF using a Dounce homogeniser (approximately ten strokes). Nuclei were pelleted by centrifugation for 15 minutes at 3,000 x g, the supernatant was collected, the pellet resuspended in the same buffer and centrifuged as above. This was repeated once more. The pooled supernatants were ultracentrifuged at 100,000 x g for 1 hour and 40 minutes in a Ti 75 rotor, the pellet resuspended in PBS/1 mM PMSF and overlayed on top of an equal volume of a 35 % (w/v) sucrose in PBS solution. Following centrifugation at 100,000 x g for 1 hour without brake in a SW 40 rotor, the membranes were collected as a cloudy interphase, and again pelleted by centrifugation at 40,000 x g for 1 hour. VM and endothelial cell membrane proteins were solubilized in 10 mM Tris-HCl, pH 7.5 with 100 mM NaCl, 10 mM EDTA, and 1 % Igepal CA-630 (Cat. no. I-3021; Sigma) containing 1 mM PMSF (cat.no. P-7626; Sigma), 1 µg/ml pepstatin A (cat.no. P-4265; Sigma) and 1 µg/ml leupeptin (cat.no. L-2023; Sigma). An equal volume of solubilized cell membrane proteins and 2 x reducing sample buffer were mixed and applied on the gel.

30

SDS-PAGE and Western blotting. SDS-PAGE was run by the method of Laemmli (Laemmli et al., 1970) with 5 % stacking gels and 8 % resolving gels using a vertical Mini-PROTEAN II electrophoresis system (Bio-Rad, Hercules, CA). Separated

proteins were electrophoretically blotted onto Hybond™-C extra membranes (Amersham) using a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad, Hercules, CA). Protein gels were stained using a silver staining kit according to the instructions of the manufacturer (Bio-Rad, Hercules, CA). Following blocking for at least 2 hrs in 3 % BSA in PBS, the membranes were probed for 2 hrs at room temperature with peroxidase-conjugated *Bandeiraea simplicifolia* isoelectin B4 (L-5391, Sigma) diluted to 1 µg/ml in PBS, pH 6.8 containing 0.2 mM CaCl₂. The membranes were washed 5 times with PBS, pH 6.8, and bound isoelectin was visualised by chemiluminescence using the ECL™ kit (Amersham). When membranes were probed with human serum, they were blocked over night with 3 % BSA in Tris-buffered saline with 0.05% Tween 20 (TTBS), incubated for 1 hour in room temperature with non-diluted AB serum or anti-Gal antibody-depleted AB serum, washed five times with TTBS, and incubated for 1 hour in room temperature with peroxidase-conjugated, F(ab)'₂ fragments of goat anti-human IgG or IgM antibodies (cat. nos. 109-036-098 and 109-036-129, respectively; Jackson ImmunoResearch Labs.). Following washing in TTBS, antibody-binding components were detected using the ECL™ kit (Amersham).

For Example 4-7. Also for Example 1-3 unless specified otherwise.

Isolation and primary culture of porcine embryonic brain cells. Brains were dissected from 27-day-old pig embryos of the Pigham strain (derived from a cross between Swedish Landrace × Yorkshire sows and Hampshire boars; Nyholm Breeding Farm, Sweden) in Hank's balanced salt solution with 0.3 µM lazaroïd U-83836E (Upjohn Inc., Kalamazoo, MI). Brain cells were isolated and grown in primary culture as described elsewhere (Brevig et al., 1997). Briefly, the meninges were removed, and the brains from each litter were pooled and cut into small pieces, which were transferred to brain-cell medium (Eagle's minimum essential medium with Earle's salts supplemented with heat-inactivated (56°C, 30 min) fetal calf serum (FCS), L-glutamine, amino acids, vitamins, penicillin, streptomycin, and sodium bicarbonate (all Life Technologies Inc., Grand Island, NY)). The tissue pieces were triturated with a flame-polished pipette, and the resulting cell suspension was filtered through an 80-

μ m-pore nylon mesh (Streno, Denmark) before diluting in brain-cell medium with 20% FCS (10 ml per brain). Aliquots of 5.0 ml cell suspension were added to poly-D-lysine (Sigma Chemical Co., St. Louis, MO) coated 50-ml culture flasks (Nunc, Denmark), and incubated at 37°C in a humidified atmosphere of 5% CO₂ in air. The medium was changed after 3 days, and again on day 6 and 9, now to brain-cell medium with 10% FCS. After 10-12 days, cultured brain cells were detached by gently sweeping across the bottoms of the culture flasks with a plastic pipette, transferred to 10-ml tubes (content of one flask to one tube), and centrifuged (100 g, 10 min). Supernatants were discarded, and the cells in the pellet were resuspended in 500 μ l PBS with 2% FCS using a syringe with a needle of 0.5 mm internal diameter. The tubes were left for 15 min at room temperature to sediment cell clusters, and the supernatants with single cells in suspension were pooled and used for subsequent analyses.

15 *Bandeiraea simplicifolia* isolectin staining of porcine embryonic brain cells.

Suspended and adherent, cultured porcine embryonic brain cells were stained with *Bandeiraea simplicifolia* isolectin B4 (BS-IB4) in order to determine the expression of the α -galactosyl epitope by flow cytometry and light microscopy, respectively. Suspensions of 5.0×10^5 brain cells in 100 μ l PBS were incubated with or without 3.0 μ g FITC-conjugated BS-IB4 (Sigma) at 4°C for 30 min, washed twice in PBS (250 g, 5 min), and analysed by flow cytometry as described below. Brain cells adherent to a culture dish were fixed in 4% paraformaldehyde in PBS for 30 min, permeabilized by 1% Triton X-100 (Sigma) in Tris-buffered saline (TBS) for 15 min, and stained by incubation with biotinylated BS-IB4 (100 μ g/ml TBS; Sigma) for 60 min, peroxidase-conjugated streptavidin (1:200 in TBS; DAKO, Denmark) for 60 min, and finally 0.05% 3,3'-diaminobenzidine (DAB; Sigma) in TBS for 15 min. Between the incubations, which were all at 20°C, the cells were thoroughly rinsed with TBS. After incubation with DAB, the cells were rinsed with TBS and distilled water, covered with Aquamount (BDH Laboratory Supplies, UK), and examined in an inverted light microscope.

Treatment of porcine embryonic brain cells with human serum and rabbit complement.

Freshly isolated porcine embryonic brain cells were split into three aliquot suspensions (3.0×10^6 cells in 2.0 ml PBS), of which one received a treatment with human serum and rabbit complement: the cells were given 8.0 ml heat-inactivated human serum
 5 (pooled from blood type AB donors), incubated for 60 min at 4°C, washed in cold PBS (400 g, 5 min), resuspended in 5.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with PBS; Cedarlane Laboratories Ltd., Hornby, Ontario), incubated for 60 min at 37°C, and finally washed in PBS (400 g, 5 min). The three cell suspensions were cultured for 10 days in separate culture flasks as
 10 described above, and cells from one culture flask, not treated prior to culture, then received an identical treatment with human serum and rabbit complement. Cells from all three cultures were analysed by flow cytometry without prior staining, to determine the content of autofluorescent macrophages and/or microglial cells.

- 15 *Isolation of human CD4 T lymphocytes.* Mononuclear cells (lymphocytes and monocytes) from two healthy blood donors were isolated from buffy coats by flotation as earlier described (Brevig et al., 1997), cooled on ice for a few minutes, and mixed with washed, paramagnetic Dynabeads M-450 CD4 (Dynal AS, Norway) to a bead-to-cell ratio of 0.6. The tubes were incubated head-over-tail at 4°C for 40 min and left in
 20 a magnetic particle concentrator (MPC; Dynal) for 3 min. The supernatants were discarded, and the positively isolated cells on the beads were washed five times in PBS with 2% FCS and resuspended in Detachabead CD4/CD8 reagent ($1.0 \mu\text{l}$ per 2.8×10^5 beads; Dynal). After incubation head-over-tail at 20°C for 50 min, the tubes were given 5 ml PBS with 2% FCS and left for 3 min in the MPC. The positively isolated
 25 cells in the supernatants were transferred to new tubes and washed, in PBS with 2% FCS, once with the MPC and once by centrifugation (500 g, 10 min).

The purity of the isolated CD4 T lymphocytes was analysed by flow cytometry after incubating 5.0×10^5 cells in 100 μl PBS with 10 μl mouse anti-human CD3/4

30 FITC/RPE (Becton Dickinson, San Jose, CA) at 4°C for 30 min and washing twice in

PBS (250 g, 5 min). Isolated cells from individual A and B contained 99.1 / and 99.7% double-positive cells, respectively.

Mixed lymphocyte-brain cell culture. A suspension of porcine embryonic brain cells, prepared as described above, were split into aliquots containing 3.0×10^6 cells in 190 μ l PBS with 2% FCS, and each aliquot was given 1.0 ml of one of the following reagents: human IgG (10 mg/ml), human IgM (2.0 mg/ml), human anti-Gal (100 μ g/ml), heat-inactivated human serum (pooled from blood type AB donors), or lymphocyte medium (90% RPMI 1640 with HEPES, 10% heat-inactivated FCS, 100 IU/ml penicillin, 100 μ g/ml streptomycin, and 2.0 mM L-glutamine; all Life Technologies). Human IgG, IgM, and anti-Gal were diluted in lymphocyte medium just prior to use. After 60 min at 4°C, the cells were washed in cold lymphocyte medium (400 g, 5 min) and resuspended in 1.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with lymphocyte medium). After 60 min at 37°C, the cells were washed (400 g, 5 min), resuspended in lymphocyte medium, and counted. About 15% of the brain cells were lost in the incubation and centrifugation steps. The cells were γ -irradiated (40 Gy), and 2.0×10^4 brain cells in 100 μ l lymphocyte medium were dispensed in wells of round-bottomed 96-well plates (Nunc). Volumes of 100 μ l lymphocyte medium containing 2.0×10^5 human CD4 T lymphocytes were added in triplicate to wells with brain cells. Wells receiving CD4 T cells and lymphocyte medium but not brain cells were used to determine the background proliferative activity of the CD4 T cells. Each well was given 1.0 μ Ci [3 H]-thymidine (Amersham, UK) 24 h prior to cell harvest. After 3-7 days of incubation at 37°C in a humidified atmosphere of 5% CO₂ in air, cells were harvested onto glass fibre filters and counted for 15 min in a 1450 MicroBeta Trilux β -counter (Wallac, Finland).

The brain-cell suspensions were analysed by flow cytometry without prior staining and after staining with propidium iodide (1.0 μ g/ml PBS; Sigma) to determine the relative number of macrophages and/or microglial cells and viable cells, respectively. Samples given propidium iodide were analysed after 10 min in the dark at room temperature.

Flow cytometry. From each sample, 1.0×10^4 ungated events were acquired on a FACSort flow cytometer (Becton Dickinson). A forward-scatter threshold was set to exclude subcellular debris.

5

Example 1 – Macrophages and/or microglial cells are autofluorescent, astrocytes are not

Unstained brain cells from 28-day-old pig fetuses were analysed with flow cytometry directly after isolation (Fresh) or after 14 days in primary culture (Cultured) (Fig. 1). Plots A and B show the green and orange fluorescence of the cells. Histograms C and D show the frequency of cells as a function of their green fluorescence, and include identical markers (M1) and the percentage of the total cell number present within the markers. Plot B shows regions set to define autofluorescent (R1) and non-autofluorescent (R2) cell populations, and plots E and F show the size (forward scatter) and granularity (side scatter) of the autofluorescent (R1) and non-autofluorescent (R2) cells.

In flow cytometric analyses of unstained cells, freshly isolated porcine fetal brain cells came out as a single population of cells without autofluorescence, while primary cultures of these cells, prepared to favour growth of astrocytes and macrophages and/or microglial cells, consisted of two cell populations: a larger population of non-autofluorescent cells and a smaller population of autofluorescent cells. The autofluorescent cells were more granular than the non-autofluorescent cells (Fig. 1). The percentage of autofluorescent cells varied considerably between the litters, even between litters of the same age (Table 1).

TABLE 1		
Percentage of Autofluorescent Cells in Primary Brain-Cell Cultures Prepared from 12 Litters of Fetal Pigs		
Age of fetuses	Brain	% autofluorescent

(days)	region ^a	cells ^b
28 ^c	WB	27.3
28	WB	25.8
28	WB	18.8
	VM	14.5
28	WB	14.1
28	WB	8.8
	VM	7.5
28	WB	7.1
28	WB	6.7
28	WB	4.1
35	WB	10.3
35	WB	5.4
42	WB	12.7
56	WB	15.6

Note. Each culture was prepared from cell suspensions derived from 6-15 brains and incubated for 12-14 days. Several cultures were pooled prior to flow cytometry to reduce variability between cultures made from the same brains.

^a WB: whole brain. VM: ventral mesencephalon.

^b Determined as shown in Figure 9.

^c Data shown in Figure 9.

Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in primary culture. Cells were directly [(CD18 - β_2 integrin subunit; only present on haemopoietic cells, e.g. macrophages) and (CD56 - NCAM isoform; present on neuroectodermal cells, NK cells, and activated T cells, but not on macrophages)] or indirectly [(CD44 - present on astrocytes, macrophages, and many other cell types), (CD4 - can be present on macrophages), and glial fibrillary acidic protein (GFAP)] immunostained using FITC-conjugated (green fluorescence) or RPE-conjugated

(orange fluorescence) antibodies (Fig. 2). The isotype control (IC) IgG₁ is the negative control for the CD18 and CD56 stainings, and the isotype control IgG_{2a} is the negative control for the CD44 and CD4 stainings. Cells were fixed and permeabilized prior to staining for GFAP. The GFAP control is a sample that received secondary antibody only. Regions were set in plots G and H to compare the GFAP staining of autofluorescent and non-autofluorescent cells. Mean green fluorescence intensity in arbitrary units: $G_{R1} = 151$, $G_{R2} = 199$, $H_{R1} = 24$, and $H_{R2} = 131$. Similar results were obtained with cultured brain cells from 35-day-old fetal pigs. Only the autofluorescent cells were CD18 positive, and only the non-autofluorescent cells were CD56 positive, while both populations were CD44 positive. Antibodies against CD4 only stained some of the autofluorescent cells, and only very faintly. The non-autofluorescent cells were stained more intensively by antibodies against the astrocyte marker glial fibrillary acidic protein (GFAP) than the autofluorescent cells (Fig. 2).

Cultured brain cells isolated from 28-day-old pig fetuses were incubated with fluorescein-labelled *E. coli* (Fig. 3). The figure shows phagocytosis of *E. coli*. Plot A shows cells from a culture that received fluorescein-labelled *E. coli* (green fluorescence) 30 min prior to flow cytometry, while plot B shows cells from an untreated culture. The confocal laser microscopy image shows a cross section of a cell stained with the lipophilic and fluorescent DiI prior to incubation with fluorescein-labelled *E. coli* and dual-channel scanning. The red pseudocolour represents membranes and other lipids stained with DiI (rhodamine optical filter sets) and the yellow pseudocolour represents fluorescein-labelled *E. coli* (fluorescein optical filter sets). Scale bar: 10 μm .

Flow cytometric analysis of brain-cell cultures incubated with fluorescein-labelled *E. coli* showed that the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, while the non-autofluorescent cell population remained as one (Fig. 3). When examined in a fluorescence microscope, the green fluorescence of the bacteria was not associated with the plasma membrane (not shown). In cultures stained with the lipophilic and fluorescent DiI and subsequently

incubated with fluorescein-labelled *E. coli*, confocal laser microscopy showed that the majority of the cells only were stained by DiI. Some cells had, however, fluorescent *E. coli* within cell borders (Fig. 3).

- 5 Porcine fetal brain cells, cultured under conditions that favour growth of astrocytes and macrophages and/or microglial cells (Castellano et al., 1991), consisted of both autofluorescent cells and non-autofluorescent cells, when analysed by flow cytometry. Autofluorescence is a known property of macrophages (Havenith et al., 1993; Nicod et al., 1989), and might be due to endogenous flavoproteins (Aubin et al., 1979; Benson et al., 1979), which are excitable by the 488-nm lasers used in this study, and can emit light in the green and orange ranges of the spectrum. The autofluorescent cells had high granularity, again typical of macrophages. To determine whether the autofluorescent cells were macrophages, we stained the cultured cells with antibodies known to react with astrocytes or macrophages, and tested the cells for phagocytic activity. The autofluorescent cells were CD18⁺CD44⁺CD56⁺GFAP⁻, strongly suggesting that these cells indeed were macrophages and/or microglial cells. Since no marker was available to distinguish between macrophages and/or microglial cells, we refer to these cells as macrophages, as this is commonly done at this early stage of brain development (Perry et al., 1988). The non-autofluorescent cells were CD18⁻CD44⁺CD56⁺GFAP⁺, suggesting that these cells were astrocytes. After incubation of cultured brain cells with fluorescein-labelled *E. coli*, the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, and fluorescence microscopy and confocal laser microscopy revealed that the fluorescent bacteria were located within the cells, as strong evidence of phagocytic activity by the autofluorescent cells. Based on their phenotypic characteristics and phagocytic activity, we conclude that the autofluorescent cells were macrophages and/or microglial cells, while the non-autofluorescent cells were astrocytes.

Example 2 – Macrophages induce proliferation of human T cells, astrocytes do not

Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in primary culture and flow sorted without prior staining into an astrocyte and a macrophage population, on the basis of cell granularity and auto-fluorescence, and the purity and viability of these populations were determined by flow cytometry (Fig. 4).

- 5 **A. Purity and viability.** Cells were stained with RPE-conjugated anti-CD56 (orange fluorescence) to determine the purity (stains astrocytes but not macrophages) or propidium iodide (orange fluorescence) to determine the viability (stains nucleic acids in cells with damaged plasma membrane). The numbers given are the percentages of macrophages (left plots) and viable cells (right plots). **B. Ability to induce human T-**
- 10 **cell proliferation.** Unseparated brain cells, sorted astrocytes, and sorted macrophages were γ -irradiated to halt proliferation and mixed with lymphocytes from either of two human individuals (H-3970 and H-3977) (5 wells per combination). As a negative control, the lymphocytes were incubated without stimulators (5 wells per
-
- combination). The proliferative activity was determined by [3 H]-thymidine
- 15 incorporation after 4 days of co-culture. Bars represent means and standard errors of means. An ANOVA was done for each individual: F_{H-3970} (df 3,16) = 8.05, $p = 1.7 \times 10^{-3}$ and F_{H-3977} (df 3,16) = 24.9, $p = 2.9 \times 10^{-6}$. Stimulator cells were compared with medium in one-sided, unpaired t tests and all p values were less than 0.01. Similar
- 20 results were obtained with brain cells from another litter of 28-day-old pig fetuses. In co-cultures of sorted astrocytes or sorted macrophages and lymphocytes from either of two human individuals, the proliferative activity was significantly higher in wells with lymphocytes only (Fig. 4B).

- Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in
- 25 primary culture and flow sorted after staining with RPE-conjugated anti-CD56 (orange fluorescence) (Fig. 5). **A. Purity and viability.** Cells were analysed by flow cytometry without further staining to determine the purity (region R1 was set to include the CD56-negative macrophages), and after staining with propidium iodide (orange fluorescence) to determine the viability. The numbers given are the percentages of
- 30 cells within region R1. The viability of the astrocyte population was 91% (determined by trypan blue exclusion). **B. Ability to induce human T-cell proliferation.** Allogeneic

mononuclear blood cells (MBC; H-8053), sorted astrocytes, and sorted macrophages were γ -irradiated (50 Gy) to halt proliferation and mixed with lymphocytes from either of two human individuals (H-3970 and H-3977) (3 wells per combination). As a negative control, the lymphocytes were incubated without stimulators (12 wells per combination). The proliferative activity was determined by [3 H]-thymidine incorporation after 4 days of co-culture. Bars represent means and standard errors of means.

There was no difference between the proliferative activity in fresh and used medium after 1, 3, and 5 days of incubation (data not shown). The proliferative activity of the lymphocytes was higher when co-cultured with sorted macrophages than when co-cultured with allogeneic mononuclear blood cells. In co-cultures of sorted astrocytes (coated with anti-CD56 antibodies) and lymphocytes from either of the two human individuals, the proliferative activity was higher in wells with lymphocytes and astrocytes than in wells with lymphocytes only, but the difference was only statistically significant for one of the individuals. An ANOVA was done for each individual: F_{H-3970} (df 3,17) = 139, $p = 3.8 \times 10^{-12}$ and F_{H-3977} (df 3,17) = 216, $p = 1.0 \times 10^{-13}$. Stimulator cells were compared with medium in one-sided, unpaired t tests and all p values were less than 0.001, except when comparing the stimulatory ability of astrocytes and medium on lymphocytes from individual H-3977 ($p = 0.08$).

Macrophages are expected to be strong inducers of human T-cell proliferation, because a subpopulation of the macrophages express MHC class II antigens. To test this, cultured porcine fetal brain cells were flow sorted into a highly purified astrocyte population (more than 98% astrocytes) and an enriched macrophage population (increase in macrophages from 14% to 73%) on the basis of cell granularity and autofluorescence, and these cell populations were co-cultured with human T lymphocytes. The results showed that astrocytes from fetal pig brain are able to induce a proliferative response in human T lymphocytes. The sorted macrophage population was an equally strong stimulator as the sorted astrocyte population, but contained 27% astrocytes and many dead cells. In order to obtain a macrophage population with

higher purity and viability, cultured porcine fetal brain cells were sorted after staining for CD56, which reduced the fluorescence overlap between the two cell populations, and fetal calf serum was added to the sample fluid to avoid incubation of the cells in serum-free PBS during sorting. By this sorting protocol, we obtained a highly enriched
5 macrophage population (increase in macrophages from 7.6% to 91%) and a highly purified astrocyte population (more than 99% astrocytes), and only a few percent of the sorted cells were dead. The sorted macrophages were strong inducers of human T-cell proliferation, even stronger than allogeneic mononuclear blood cells. The sorted astrocytes, which were coated by anti-CD56 antibodies, were only weak stimulators,
10 and with one of the two human individuals, the T-cell proliferation was not significantly higher than the background proliferative activity.

Example 3 - The α -galactosyl epitope is expressed on macrophages and/or microglial cells and not on neurons.

15

Pig embryonic brain cells, including neurons, glia, microglial cells and endothelial cells, from cell suspensions of VM cells were analysed by flow cytometry for expression of α -galactosyl epitopes using biotinylated *Bandeiraea simplicifolia* isolectin (BS-IB4) (Fig. 6A). A slight shift in fluorescence of less than one log was
20 noted for the bulk population of brain cells when compared to the control. FITC-conjugated avidin alone was used as the control. This should be compared to BS-IB4 staining of PLMECs where a shift to the right on the logarithmic scale of at least two ten log steps was seen (Fig. 6B).

25 In order to verify our flow cytometry data, we ran a Western blot analysis on BS-IB4 reactive, solubilized glycoproteins isolated from cell membranes of VM, PLMEC and ECV cells following separation on 8% SDS-PAGE, in order to detect possible proteins carrying α -galactosyl epitopes. PLMECs were shown to express high levels of α -galactosyl epitopes (Fig. 7); epitopes that were carried on several different protein
30 backbones as indicated by staining of components with molecular weights ranging from high (> 220 kDa) to low (≤ 30 kDa) mass. Detection was accomplished by

chemiluminescence and the two blots represent 5 and 10 second-exposures, respectively. Upon longer exposure times (> 10 seconds), we saw weak staining in the VM lane of a component of approximately 150 kDa size. Under these conditions, a component of similar size and staining intensity was seen among the ECV membrane proteins (Fig. 7). The distribution of α -galactosyl epitopes on individual cell populations of VM cells was examined using BS-IB4 immunohistochemistry. Fig. 8 shows a sagittal section of the VM of a 27 day-old pig embryo stained immunohistochemically for tyrosine hydroxylase, which is the rate limiting enzyme for dopamine production in dopaminergic neurons. Cell bodies and some axonal fibres are seen (Fig. 8A). Low power magnification of a coronal section of a 27 day-old pig embryo stained immunohistochemically using peroxidase-conjugated BS-IB4 isolectin (Fig. 8B). There is intense staining of embryonic brain microvascular endothelium (Fig. 8B), and a somewhat less intense staining of microglial cells/tissue resident macrophages as seen at higher magnification (Fig. 8C). No prominent staining was found on neural or glia cells. Staining of cells similar in morphology to the BS-IB4 stained cells in panel C, was seen with a mouse mAb specific for monocytes/tissue macrophages, which also binds porcine microglial cells (Fig. 8D).

It is conceivable that the staining of VM membrane proteins, which was of approximately the same intensity as the staining of ECV proteins, may be due to a recognition of determinants related to α -Gal. However, isolectin-histochemistry indicated that the majority of the α -Gal expression is restricted to endothelial cells and microglial cells/macrophages, and not to neural cells, in fetal porcine brain tissue (Fig. 8). BS-IB4 reactivity in the adult mouse brain has also been shown to be confined to capillaries (Peters et al., 1979). Therefore, a more likely explanation for our observed low level expression in the Western blot experiments, is that the α -Gal expressing cells constitute only a small fraction of the total number of cells in the suspended VM cell graft. The flow cytometry data (Fig. 6A), however, shows a shift of the majority of VM cells and may not reflect the expression seen on endothelial and microglial cells in isolectin-histochemistry (Fig. 8).

Example 4 - Purification of antibodies from human serum

Human IgG, IgM, and anti-Gal were purified from serum pooled from more than 20 healthy, blood type AB donors using beaded agarose with goat anti-human IgG (Fc specific; Sigma), goat anti-human IgM (μ -chain specific; Sigma), or porcine thyroglobulin (source of α -galactosyl epitope; Sigma), respectively. Five ml of slurry (2.5 ml of packed beads) were poured into a column of 10 mm diameter and washed with PBS. Heat-inactivated human serum (40 ml) was applied at 0.5 ml/min using a peristaltic pump, the agarose was washed with several column volumes of PBS, and bound protein was eluted with 0.1 M glycine/HCl (pH 2.5) at 1.0 ml/min. One-millilitre fractions were collected in tubes containing 0.1 ml neutralising buffer (1.5 M Tris/HCl, pH 8.8). The absorption at 280 nm was read spectrophotometrically, and contents of tubes containing protein were pooled, dialysed against 1% PBS, lyophilised, and resuspended in distilled water (1/100 of eluted volume). The protein concentration was determined using a BCA Protein Assay Reagent Kit (Pierce, Rockford, IL) according to the manufacturer's instructions.

The purity of the IgG and IgM preparations was analysed by SDS-PAGE: 4.0 μ g of each sample was boiled in SDS reducing or non-reducing buffer for 5 min and loaded onto ready-made, 4-15% continuous gels (Bio-Rad, Hercules, CA). After electrophoresis, the gels were stained using a silver-staining kit (Bio-Rad) according to the manufacturer's instructions. No IgM bands appeared in the IgG lanes, but weak IgG bands were present in the IgM lanes.

The α -galactosyl-epitope reactivity of the antibodies purified from human serum using porcine thyroglobulin was assessed by incubating 5.0×10^5 Raji cells (human Burkitt lymphoma cell line) or Raji cells transfected and selected to stably express the porcine α 1,3 galactosyl transferase gene (Raji-GT cells) in 100 μ l PBS with or without 10 μ g of the purified antibodies. After 60 min at 4°C, the cells were washed once in PBS (250 g, 5 min), incubated with rabbit anti-human IgG F(ab')₂ FITC (1:10; DAKO) or rabbit anti-human IgM F(ab')₂ FITC (1:10; DAKO) at 4°C for 60 min, washed twice

in PBS (250 g, 5 min), and analysed by flow cytometry. The expression of the α -galactosyl epitope on Raji-GT cells was verified by staining Raji-GT cells and Raji cells with 3.0 μ g FITC-conjugated BS-IB4. Transfection and selection of the Raji-GT cell line has been described by Kumagai-Braesch et al. (1998).

5

Example 5 – Macrophages and/or microglial cells cultured from embryonic pig brain tissue express the α -galactosyl epitope

Porcine embryonic brain cells were grown in primary culture with a high serum
10 content in the medium, conditions which produce autofluorescent macrophages and/or microglial cells and non-autofluorescent astrocytes, as shown in Brevig et al., 1999, in press. See Example 1 for details.

Cultured cells were analysed unstained and after staining with FITC-conjugated
15 *Bandeiraea simplicifolia* isolectin B4 (BS-IB4 FITC) by flow cytometry. The dotplots show the intensity of green (FL1) and orange (FL2) fluorescence (see Fig. 9), and contain a line that separates autofluorescent macrophages and/or microglial cells (m) from non-autofluorescent astrocytes (a). Staining resulted in an increase in green-
20 fluorescence geometric means of 1167 units for macrophages and/or microglial cells and 16 units for astrocytes. Thus, macrophages and/or microglial cells express the α -galactosyl epitope, but it is not clear whether the weak staining of astrocytes reflects low α -galactosyl-epitope expression or unspecific binding of BS-IB4 FITC. Note the logarithmic scales on the axes. The photomicrograph (300 \times) shows adherent, cultured
25 brain cells which were fixed, permeabilized, and stained with biotinylated BS-IB4 and peroxidase-conjugated streptavidine. The BS-IB4-positive cells are rounded with the DAB staining product concentrated on the cell membrane.

As shown by McKenzie et al., 1995, the α -galactosyl epitope expression may change
when porcine tissue is cultured, but macrophages and/or microglial cells from
30 embryonic pig brain maintained their α -galactosyl epitope expression in culture (Fig. 9).

Example 6 - Human serum and rabbit complement remove macrophages and/or microglial cells from cultured and freshly isolated porcine embryonic brain cells

- 5 Dissociated brain tissue was split into aliquots, of which one was treated with human serum and rabbit complement prior to culture for 10 days, and another received an identical treatment after culture. These cells and untreated, cultured cells were analysed by flow cytometry without prior staining to compare the content of macrophages and/or microglial cells. In Fig. 10 the histograms show the cell frequency
10 as a function of green-fluorescence intensity (FL1), and contain identical markers (M1) to define the autofluorescent macrophages and/or microglial cells and the percentage of the cells that are within the markers. Both when applied to freshly isolated cells and to cells grown in primary culture, treatment with human serum and rabbit complement reduced the relative number of macrophages and/or microglial
15 cells.

Example 7 - Treatment of porcine brain cells with anti-Gal and complement reduces content of macrophages and/or microglial cells and ability to induce human CD4 T-cell proliferation

- 20 Raji cells (Raji) and Raji cells transfected to express porcine α 1,3 galactosyl transferase (and thus the α -galactosyl epitope; Raji-GT) were incubated with the antibodies against the α -galactosyl epitope (purified from normal serum as described in Example 4; in Fig. 11 referred to as aGal) or no antibodies and stained with either
25 FITC-conjugated anti-human IgG (aIgG) or FITC-conjugated anti-human IgM (aIgM). The expression of the α -galactosyl epitope on Raji-GT cells was verified by staining these and Raji cells with FITC-conjugated BS-IB4. The purified antibodies contained both IgG and IgM reactive with Raji-GT cells, but not with Raji cells. Unspecific staining of Raji-GT cells by aIgG and aIgM was minimal, and the purified antibodies
30 thus contained both IgG and IgM reactive to the α -galactosyl epitope (see Fig. 11).

Porcine embryonic brain cells were grown in primary culture for 12 days, dissociated, and incubated with human IgG (circle in Fig. 12), human IgM (square in Fig. 12), human anti-Gal (triangle in Fig. 12), human serum (diamond in Fig. 12), or medium (filled circle in Fig. 12). Human IgG, IgM and anti-Gal were prepared as described in

- 5 Example 4. After 60 min at 4°C, the cells were washed, resuspended in medium with rabbit complement, incubated at 37°C for 60 min, washed again, γ -irradiated to halt their proliferation, and mixed with highly purified human peripheral blood CD4 T cells. CD4 T cells were also grown in absence of brain cells to determine their background proliferative activity (cross in Fig. 12). Proliferation was determined as
- 10 incorporation of tritiated thymidine, and means of triplicate cultures are given in counts per minute (cpm) as shown in Fig. 12. Bars represent one SEM. IgG and IgM reactive with the α -galactosyl epitope were present in the anti-Gal preparation (Fig. 11). The effect of the different brain-cell pretreatments on content of macrophages and/or microglial cells and cell viability is given in Table 2 below.

15

Table 2. Content of macrophages and/or microglial cells and cell viability of pretreated porcine embryonic brain cells for co-culture with human CD4 T lymphocytes		
Pretreatment	Macrophages and/or microglial cells (%)	Viable cells (%)
Human IgG	1.4	83.2
Human IgM	1.1	87.5
Human anti-Gal	0.8	87.1
Human serum	1.1	89.6
Medium	3.4	87.5

- Cultured porcine embryonic brain cells treated with human IgG, human IgM, human anti-Gal, or human serum and rabbit complement contained only 0.8-1.4% macrophages and/or microglial cells and did not induce proliferation of human CD4 T
- 20 cells, while brain cells given a control treatment with medium and rabbit complement

contained 3.4% macrophages and/or microglial cells and induced a significant proliferative response in human CD4 T cells.

5 Even though human IgG, human IgM, human anti-Gal, and human serum were not equally effective at removing macrophages and/or microglial cells (Table 2), the proliferative response of the CD4 T cells to the remaining brain cells was not higher than background activity (Fig. 12). This suggests the presence of a threshold, below which the macrophages and/or microglial cells are too few to elicit a T-cell response in vitro, and possibly in vivo. Another explanation could be that proteins on the
10 remaining macrophages and/or microglial cells, which are required for them to start a T-cell response by the direct pathway, are masked by anti-Gal. The latter explanation is consistent with a previous finding that porcine embryonic brain cells treated with heat-inactivated human serum, and no subsequent treatment with complement, have reduced capacity to induce proliferation of human T lymphocytes (Brevig et al., 1997).

15

An in vitro model was used to study the human CD4 T-cell response to porcine embryonic brain cells (Fig. 13). The brain cells were grown in primary culture prior to co-culture with human CD4 T cells, because only cultured cells, and not freshly isolated cells, will induce proliferation of human T cells (Brevig et al., 1997).

20 Culturing under the conditions described herein, like intracerebral transplantation (Mason et al., 1986; Duan et al., 1995), upregulates the expression of MHC antigens (Brevig et al., 1999, in press).

Fig. 13 shows a summary of the effect of anti-Gal and complement (C) on dissociated
25 porcine brain tissue in the clinical situation and in the in-vitro model used by the inventors. Dissociated brain tissue from pig embryos contains neurons (N), astrocytes (A), macrophages and/or microglial cells (M), and endothelial cells (E). The latter two cell types express the α -galactosyl epitope (α -Gal), and their removal prior to transplantation will greatly reduce the potential of the donor tissue to upregulate MHC
30 antigens, particularly class II, once implanted. Primary culture in medium with a high serum content favours growth of astrocytes and macrophages, and upregulates the

expression of MHC antigens. Dissociated porcine brain tissue cultured under these conditions can thus be used to study the human T-cell response to porcine neural xenografts in vitro.

- 5 The approach of the inventors, which is shown in Figure 13, was (i) to target the α -galactosyl epitope, because it is expressed on macrophages and/or microglial cells, but not on neurons, in fresh porcine brain tissue (Sumitran et al., 1999, in press), and (ii) to use antibody- and complement-mediated lysis, since even macrophages and/or microglial cells within small cell clusters can be removed by this mechanism.

10

Pretreatment of dissociated porcine brain tissue with anti-Gal and complement probably also removes endothelial cells, because the α -galactosyl epitope is abundantly expressed on endothelial cells in embryonic pig brain (Sumitran et al.,

- 15 1999), and porcine aortic endothelial cells are sensitive to lysis by anti-Gal and complement (Vaughan et al., 1994). In culture, porcine aortic endothelial cells constitutively express class I, but not class II MHC antigens, and induce proliferation of human CD8, but not CD4 T cells (Murray et al., 1994). After culture with human tumour necrosis factor- α , which may be present in neural grafts due to surgically induced inflammation, porcine aortic endothelial cells also express MHC class II
- 20 antigens and induce proliferation of human CD4 T cells (Batten et al., 1996). Removal of endothelial cells may thus be beneficial for the survival of neural xenografts, but it is not known whether donor-derived endothelial cells are necessary for xenograft neovascularization in humans. However, in an allogeneic rat model, whole-suspension grafts and grafts depleted of microglial cells and endothelial cells developed
- 25 identically in terms of neovascularization and colonisation by host microglial cells (Pennell and Streit, 1997).

References

- 30 Aubin, J. E. 1979. Autofluorescence of viable cultured mammalian cells. *J. Histochem. Cytochem.* 27: 36-43.

- Auchincloss H, Sachs DH (1998) Xenogeneic transplantation. *Annu Rev Immunol* 16:433-470.
- Bartlett PF, Rosenfeld J, Bailey KA, Cheesman H, Harvey AR, Kerr RS (1990) Allograft rejection overcome by immunoselection of neuronal precursor cells. *Prog Brain Res* 82:153-160.
- 5 Batten P, Yacoub MH, Rose ML (1996) Effect of human cytokines (IFN- γ , TNF- α , IL-1 β , IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes. *Immunology* 87:127-133.
- Benson, R. C., R. A. Meyer, M. E. Zaruba, and G. M. McKhann. 1979. Cellular autofluorescence – is it due to flavins? *J. Histochem. Cytochem.* 27: 44-48.
- 10 Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, Sanberg PR (1996) CNS immunological modulation of neural graft rejection and survival. *Neurol Res* 18:297-304.
-
- Borlongan CV, Sanberg PR, Freeman TB (1999) Neural transplantation for neurodegenerative disorders. *Lancet* 353 Suppl 1:29-30.
- 15 Brevig T, Pedersen EB, Kristensen T, Zimmer J (1997) Proliferative response of human T lymphocytes to porcine fetal brain cells. *Cell Transplant* 6:571-577.
- Brevig T, Kristensen T, Zimmer J (1999) Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain. *Exp Neurol* (in press).
- 20 Castellano, B., B. Gonzalez, M. B. Jensen, E. B. Pedersen, B. R. Finsen, and J. Zimmer. 1991. A double staining technique for simultaneous demonstration of astrocytes and microglia in brain sections and astroglial cell cultures. *J. Histochem. Cytochem.* 39: 561-568.
- 25 Cozzi E, White DJ (1995) The generation of transgenic pigs as potential organ donors for humans. *Nature Med* 1:964-966.
- Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O (1997) Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. *Nature Med* 3:350-353.
- 30

- Dorling A, Lombardi G, Binns R, Lechler RI (1996) Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. *Eur J Immunol* 26:1378-1387.
- 5 Duan W-M, Widner H, Brundin P (1995) Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. *Exp Brain Res* 104:227-242.
- Dunnett SB, Björklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. *Nature* 399 Suppl:A32-A39.
- 10 Edge AS, Gosse ME, Dinsmore J (1998) Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. *Cell Transplant* 7:525-539.
- Galili U (1993) Interaction of the natural anti-Gal antibody with α -galactosyl epitopes: a major obstacle for xenotransplantation in humans. *Immunol Today* 14:480-482.
- Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O (1996)
-
- 15 Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. *Exp Neurol* 140:1-13.
- Gill RG, Wolf L (1995) Immunobiology of cellular transplantation. *Cell Transplant* 4:361-370.
- 20 Grabowska A, Lampson LA (1992) Expression of class I and II major histocompatibility complex (MHC) antigens in the developing CNS. *J Neural Transplant Plast* 3:204-205.
- Grasbon-Frodl, E. M., Nakao, N., and Brundin, P. 1996. The lazaroïd U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4 degrees C and subsequently used for cultures or intracerebral transplantation. *Brain Res. Bull.*
- 25 39: 341-347.
- Hallberg, E.C., Holgersson, J., and Samuelsson, B.E. (1998) Glycosphingolipid expression in pig aorta. Identification of possible target antigens for human natural antibodies. *Glycobiology* 8, 637-649.
- 30 Havenith, C. E., A. J. Breedijk, M. P. van, N. Blijleven, W. Calame, R. H. Beelen, and E. C. Hoefsmit. 1993. Separation of alveolar macrophages and dendritic cells via

autofluorescence: phenotypical and functional characterization. *J. Leukoc. Biol.* 53: 504-510.

Huffaker TK, Boss BD, Morgan AS, Neff NT, Strecker RE, Spence MS, Miao R (1989) Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. *Exp Brain Res* 77:329-336.

Isacson O, Breakefield XO (1997) Benefits and risks of hosting animal cells in the human brain. *Nature Med* 3:964-969.

Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH (1995) Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. *Nature Med* 1:1189-1194.

Jacobs, D., and Pipho, C. 1983. Use of propidium iodide staining and flow cytometry to measure antibody-mediated cytotoxicity: resolution of complement-sensitive and resistant target cells. *J. Immunol. Meth.* 62: 101-108.

15 Kaufman CL, Gaines BA, Ildstad ST (1995) Xenotransplantation. *Annu Rev Immunol* 13:339-367.

Kirk AD, Li RA, Kinch MS, Abernethy KA, Doyle C, Bollinger RR (1993) The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. *Transplantation* 55:924-931.

20 Kohler and Milstein (1975) *Nature* 256: 495-497.

Korsgren O (1997) Acute cellular xenograft rejection. *Xenotransplantation* 4:11-19.

Kumagai-Braesch M, Satake M, Korsgren O, Andersson A, Möller E (1993) Characterization of cellular human anti-porcine xenoreactivity. *Clin Transplant* 7:273-280.

25 Kumagai-Braesch M, Satake M, Qian Y, Holgersson J, Möller E (1998) Human NK cell and ADCC reactivity against xenogeneic porcine target cells including fetal porcine islet cells. *Xenotransplantation* 5:132-145.

Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.

- Lampson LA (1995) Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. *Microsc Res Tech* 32:267-285.
- 5 Liu, J., Qian, Y., and Holgersson, J. (1997) Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal α 1,3Gal epitope. *Transplantation* 63, 1673-1682.
- Mason DW, Charlton HM, Jones AJ, Lavy CB, Puklavec M, Simmonds SJ (1986) The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. *Neuroscience* 19:685-694.
- 10 McKenzie IFC, Koulmanda M, Mandel TE, Xing P-X, Sandrin MS (1995) Pig-to-human xenotransplantation: the expression of Gal α (1-3)Gal epitopes on pig islet cells. *Xenotransplantation* 2:1-7.
-
- Murray AG, Khodadoust MM, Poher JS, Bothwell AL (1994) Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and
- 15 costimulation by ligands for human CD2 and CD28. *Immunity* 1:57-63.
- Nakao, N., Frodl, E. M., Duan, W. M., Widner, H., and Brundin, P. 1994. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. *Proc. Natl. Acad. Sci. USA* 91: 12408-12412.
- Nicod, L. P., M. F. Lipscomb, G. B. Toews, and J. C. Weissler. 1989. Separation of
- 20 potent and poorly functional human lung accessory cells based on autofluorescence. *J. Leukoc. Biol.* 45 : 458-465.
- Okura Y, Tanaka R, Ono K, Yoshida S, Tanuma N, Matsumoto Y (1997) Treatment of rat hemiparkinson model with xenogeneic neural transplantation: tolerance induction by anti-T-cell antibodies. *J Neurosci Res* 48:385-396.
- 25 Olanow CW, Freeman TB, Kordower JH (1997) Neural transplantation as a therapy for Parkinson's disease. *Adv Neurol* 74:249-269.
- Pakzaban P, Deacon TW, Burns LH, Dinsmore J, Isacson O (1995) A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central
- 30 nervous system. *Neuroscience* 65:983-996.

- Pennell NA, Streit WJ (1997) Colonization of neural allografts by host microglial cells: relationship to graft neovascularization. *Cell Transplant* 6:221-230.
- Perry, V. H., and S. Gordon. 1988. Macrophages and microglia in the nervous system. *Trends. Neurosci.* 11: 273-277.
- 5 Peschanski M, Cesaro P, Hantraye P (1995) Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. *Neuroscience* 68:273-285.
- Peters, B. P., and Goldstein, I. J. 1979. The use of fluorescein-conjugated *Bandeiraea simplicifolia* B₄-isolectin as a histochemical reagent for the detection of α -D-galactopyranosyl groups. *Exp. Cell Res.* 120: 321-334.
- 10 Pierson RN, Winn HJ, Russell PS, Auchincloss H (1989) Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. *J Exp Med* 170:991-996.
- Rother RP, Squinto SP (1996) The α -galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. *Cell* 86:185-188.
-
- 15 Satake M, Korsgren O, Ridderstad A, Karlsson PA, Wallgren AC, Möller E (1994) Immunological characteristics of islet cell xenotransplantation in humans and rodents. *Immunol Rev* 141:191-211.
- Sumitran S, Liu J, Czech KA, Christensson B, Widner H, Holgersson J (1999) Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Gal α 1,3Gal-based xenoantigens. *Exp Neurol* (in press).
- 20 Vaughan HA, Loveland BE, Sandrin MS (1994) Gal α (1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. *Transplantation* 58:879-882.
- Wennberg L, Wallgren AC, Sundberg B, Rafael E, Zhu S, Tibell A, Karlsson PA, Groth CG, Korsgren O (1995) Efficacy of immunosuppressive drugs in islet xenotransplantation: a study in the pig-to-rat model. *Xenotransplantation* 2:222-229.
- 25 Wood MJ, Sloan DJ, Wood KJ, Charlton HM (1996) Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. *Neuroscience* 70:775-789.
- 30 Yamada K, Sachs DH, DerSimonian H (1995) Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. *J Immunol* 155:5249-5256.

Zawada WM, Cibelli JB, Choi PK, Clarkson ED, Golueke PJ, Witta SE, Bell KP, Kane J, Ponce-de LF, Jerry DJ, Robl JM, Freed CR, Stice SL (1998) Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats. *Nature Med* 4:569-574.

Claims

1. Use of a molecule that binds to macrophages and/or microglia cells, preferably to the Gal α 1-3Gal β 1-R terminated epitopes, in order to remove and/or mask
5 macrophages/microglial cells in order to treat a non-human graft to diminish graft immunogenicity and/or rejection in the human body.
 2. Use according to claim 1, wherein the molecule is an antibody.
 - 10 3. Use according to claim 1-2, wherein the non-human graft is a porcine graft, preferably a porcine neural graft, in particular a graft derived from porcine embryonic and/or fetal neural tissue.
-
- 15 4. A process for removal of macrophages and/or microglial cells from non-human grafts, characterised in that
 - (a) the graft, preferably an embryonic and/or fetal neural tissue, is dissociated, possibly also converted to a single-cell suspension,
 - (b) the dissociated tissue is treated with a molecule that binds to macrophages and/or microglial cells, preferably an antibody, especially an antibody against the Gal α 1-
20 3Gal β 1-R epitope, and possibly also a complement reagent,
 - (c) the macrophages and/or microglial cells are deleted from the graft by coupling of the binding molecule to a carrier or by flow sorting, or
 - (d) the macrophages and/or microglial cells are lysed with the antibody and the
25 complement reagent.
 5. A process according to claim 4, characterised in that
 - (a) porcine embryonic and/or fetal neural tissue is dissociated,
 - (b) the dissociated tissue is treated with antibodies, preferably human antibodies,
30 against the Gal α 1-3Gal β 1-R epitope and complement reagent in order to remove and/or mask macrophages and/or microglial cells.

6. A process for preparation of an antibody that binds to macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope, characterised in that the antibody is purified from human serum from blood type AB donors by affinity chromatography with, for example, porcine thyroglobulin as a source of the epitope.

5

7. An antibody against macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope.

8. A composition, comprising an antibody according to claim 7, together with a complement reagent.

10

9. A composition according to claim 8, wherein the complement reagent is Low-Tox-M complement.

10. A process for treatment of neurological disorders, such as Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy and spinal cord injuries, characterised in that

15

(a) porcine embryonic and/or fetal neural tissue is dissociated,

(b) the dissociated tissue is treated with antibodies, preferably human antibodies,

against the Gal α 1-3Gal β 1-R epitope, and complement in order to remove and/or mask macrophages and/or microglial cells,

20


(c) the dissociated and antibody- and complement-treated tissue is transplanted into the human body.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Abstract

The present invention relates to the use of molecules that bind to macrophages and/or microglial cells in order to mask and/or remove macrophages and/or microglial cells in order to treat a non-human graft to diminish the immunogenicity and/or rejection of the graft. The molecule could bind to the Gal α 1-3Gal epitope and could e.g. be an antibody. The graft could e.g. be a porcine neural graft. The invention also relates to a process for removal of cells, such as macrophages and/or microglial cells. The invention also relates to a process for preparation of an antibody as mentioned above. Furthermore, the invention relates to an antibody that binds to macrophages and/or microglial cells, preferably the Gal α 1-3Gal β 1-R epitope, as well as a composition comprising such an antibody and a complement reagent. Finally, the invention relates to a process for treatment of neurological disorders with such pretreated porcine neural grafts.

B
I
O
P
A
T
E
N
T

**Fig. 1**





Fig. 2



COLOR




Fig. 3

3000415






Fig. 4



B




Fig. 5




Fig. 6




Fig. 7

000001-5




Fig. 8




Fig. 9

890808-13




Fig. 10

99-08-25-13




Fig. 11




Fig. 12




Fig. 13

